Literature DB >> 26516144

aBETting therapeutic resistance by Wnt signaling.

Carl G Engelke1,2, Arul M Chinnaiyan1,2,3,4,5.   

Abstract

BET inhibition has emerged as a promising epigenetic therapy for malignancies in the last five years, but little consensus has developed regarding what may mediate the axis between sensitivity and resistance. Two recent papers published in Nature attempt to address this question in acute myeloid leukemia (AML) and independently identify the Wnt signaling pathway as a driver and biomarker of therapeutic resistance.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26516144      PMCID： PMC4650429          DOI： 10.1038/cr.2015.127

Source DB:  PubMed          Journal:  Cell Res        ISSN： 1001-0602            Impact factor:   25.617


  11 in total

1.  BET bromodomain inhibition as a therapeutic strategy to target c-Myc.

Authors:  Jake E Delmore; Ghayas C Issa; Madeleine E Lemieux; Peter B Rahl; Junwei Shi; Hannah M Jacobs; Efstathios Kastritis; Timothy Gilpatrick; Ronald M Paranal; Jun Qi; Marta Chesi; Anna C Schinzel; Michael R McKeown; Timothy P Heffernan; Christopher R Vakoc; P Leif Bergsagel; Irene M Ghobrial; Paul G Richardson; Richard A Young; William C Hahn; Kenneth C Anderson; Andrew L Kung; James E Bradner; Constantine S Mitsiades
Journal:  Cell       Date:  2011-09-01       Impact factor: 41.582

Review 2.  Wnt signaling in stem and cancer stem cells.

Authors:  Jane D Holland; Alexandra Klaus; Alistair N Garratt; Walter Birchmeier
Journal:  Curr Opin Cell Biol       Date:  2013-01-21       Impact factor: 8.382

Review 3.  Targeting Notch, Hedgehog, and Wnt pathways in cancer stem cells: clinical update.

Authors:  Naoko Takebe; Lucio Miele; Pamela Jo Harris; Woondong Jeong; Hideaki Bando; Michael Kahn; Sherry X Yang; S Percy Ivy
Journal:  Nat Rev Clin Oncol       Date:  2015-04-07       Impact factor: 66.675

Review 4.  The mechanisms behind the therapeutic activity of BET bromodomain inhibition.

Authors:  Junwei Shi; Christopher R Vakoc
Journal:  Mol Cell       Date:  2014-06-05       Impact factor: 17.970

5.  Selective inhibition of tumor oncogenes by disruption of super-enhancers.

Authors:  Jakob Lovén; Heather A Hoke; Charles Y Lin; Ashley Lau; David A Orlando; Christopher R Vakoc; James E Bradner; Tong Ihn Lee; Richard A Young
Journal:  Cell       Date:  2013-04-11       Impact factor: 41.582

6.  BET inhibitor resistance emerges from leukaemia stem cells.

Authors:  Chun Yew Fong; Omer Gilan; Enid Y N Lam; Alan F Rubin; Sarah Ftouni; Dean Tyler; Kym Stanley; Devbarna Sinha; Paul Yeh; Jessica Morison; George Giotopoulos; Dave Lugo; Philip Jeffrey; Stanley Chun-Wei Lee; Christopher Carpenter; Richard Gregory; Robert G Ramsay; Steven W Lane; Omar Abdel-Wahab; Tony Kouzarides; Ricky W Johnstone; Sarah-Jane Dawson; Brian J P Huntly; Rab K Prinjha; Anthony T Papenfuss; Mark A Dawson
Journal:  Nature       Date:  2015-09-14       Impact factor: 49.962

7.  Sensitivity of human lung adenocarcinoma cell lines to targeted inhibition of BET epigenetic signaling proteins.

Authors:  William W Lockwood; Kreshnik Zejnullahu; James E Bradner; Harold Varmus
Journal:  Proc Natl Acad Sci U S A       Date:  2012-11-05       Impact factor: 11.205

8.  BET inhibitors induce apoptosis through a MYC independent mechanism and synergise with CDK inhibitors to kill osteosarcoma cells.

Authors:  Emma K Baker; Scott Taylor; Ankita Gupte; Phillip P Sharp; Mannu Walia; Nicole C Walsh; Andrew Cw Zannettino; Alistair M Chalk; Christopher J Burns; Carl R Walkley
Journal:  Sci Rep       Date:  2015-05-06       Impact factor: 4.379

9.  Transcriptional plasticity promotes primary and acquired resistance to BET inhibition.

Authors:  Philipp Rathert; Mareike Roth; Tobias Neumann; Felix Muerdter; Jae-Seok Roe; Matthias Muhar; Sumit Deswal; Sabine Cerny-Reiterer; Barbara Peter; Julian Jude; Thomas Hoffmann; Łukasz M Boryń; Elin Axelsson; Norbert Schweifer; Ulrike Tontsch-Grunt; Lukas E Dow; Davide Gianni; Mark Pearson; Peter Valent; Alexander Stark; Norbert Kraut; Christopher R Vakoc; Johannes Zuber
Journal:  Nature       Date:  2015-09-14       Impact factor: 49.962

10.  Bromodomain protein BRD4 is required for estrogen receptor-dependent enhancer activation and gene transcription.

Authors:  Sankari Nagarajan; Tareq Hossan; Malik Alawi; Zeynab Najafova; Daniela Indenbirken; Upasana Bedi; Hanna Taipaleenmäki; Isabel Ben-Batalla; Marina Scheller; Sonja Loges; Stefan Knapp; Eric Hesse; Cheng-Ming Chiang; Adam Grundhoff; Steven A Johnsen
Journal:  Cell Rep       Date:  2014-07-10       Impact factor: 9.423
View more
  4 in total

Review 1.  Drugging the 'undruggable' cancer targets.

Authors:  Chi V Dang; E Premkumar Reddy; Kevan M Shokat; Laura Soucek
Journal:  Nat Rev Cancer       Date:  2017-06-23       Impact factor: 60.716

2.  WNT974 Inhibits Proliferation, Induces Apoptosis, and Enhances Chemosensitivity to Doxorubicin in Lymphoma Cells by Inhibiting Wnt/β-Catenin Signaling.

Authors:  Senmin Chen; Xiuli Yuan; Huanli Xu; Meng Yi; Sixi Liu; Feiqiu Wen
Journal:  Med Sci Monit       Date:  2020-06-29

3.  Bromodomain inhibitor jq1 induces cell cycle arrest and apoptosis of glioma stem cells through the VEGF/PI3K/AKT signaling pathway.

Authors:  Naiyan Wen; Baofeng Guo; Hongwu Zheng; Libo Xu; Hang Liang; Qian Wang; Ding Wang; Xuyang Chen; Shengnan Zhang; Yang Li; Ling Zhang
Journal:  Int J Oncol       Date:  2019-08-29       Impact factor: 5.650

4.  Angelica gigas Nakai and Decursin Downregulate Myc Expression to Promote Cell Death in B-cell Lymphoma.

Authors:  Eungyoung Kim; Jehyun Nam; Woochul Chang; Ismayil S Zulfugarov; Zhanna M Okhlopkova; Daniil Olennikov; Nadezhda K Chirikova; Sang-Woo Kim
Journal:  Sci Rep       Date:  2018-07-12       Impact factor: 4.379
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.